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Clinical barriers to stem-cell therapy include the need for efﬁcient derivation of histocompatible stem cells
and the zoonotic risk inherent to human stem-cell xenoculture on mouse feeder cells. We describe a
system for efﬁciently deriving induced pluripotent stem (iPS) cells from human and mouse amniocytes,
and for maintaining the pluripotency of these iPS cells on mitotically inactivated feeder layers prepared
from the same amniocytes. Both cellular components of this system are thus autologous to a single
donor. Moreover, the use of human feeder cells reduces the risk of zoonosis. Generation of iPS cells
using retroviral vectors from short- or long-term cultured human and mouse amniocytes using four factors,
or two factors in mouse, occurs in 5–7 days with 0.5% efﬁciency. This efﬁciency is greater than that reported
for mouse and human ﬁbroblasts using similar viral infection approaches, and does not appear to result from
selective reprogramming of Oct4
1 or c-Kit
1 amniocyte subpopulations. Derivation of amniocyte-derived iPS
(AdiPS) cell colonies, which express pluripotency markers and exhibit appropriate microarray expression
and DNA methylation properties, was facilitated by live immunostaining. AdiPS cells also generate embryoid
bodies in vitro and teratomas in vivo. Furthermore, mouse and human amniocytes can serve as feeder layers
for iPS cells and for mouse and human embryonic stem (ES) cells. Thus, human amniocytes provide an efﬁ-
cient source of autologous iPS cells and, as feeder cells, can also maintain iPS and ES cell pluripotency with-
out the safety concerns associated with xenoculture.
INTRODUCTION
Recent advances in stem-cell biology hold the potential to
change the treatment of many diseases, including neurodegen-
erative diseases, diabetes, myocardial infarction, stroke and
spinal cord injury. Central to this paradigm is the requirement
for patient-speciﬁc stem cells that can be propagated in a cell-
culture environment suitable for transplantation and other
therapeutic applications. Presently, NIH-approved human ES
(hES) cell lines are most typically cultured on mitotically inac-
tivated mouse embryonic ﬁbroblast (MEF) cells as xenogenic
feeder cells (1). Due to concerns about the transmission of
zoonotic infections to recipients, xenoculture represents a sig-
niﬁcant impediment to stem-cell therapy. At present, the use
of federal registry hES cells and stem-cell derivatives that
involve feeder layer xenoculture requires detailed testing for
adventitious infectious agents, according to the established
FDA guidelines for xenotransplantation. According to these
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tation of human cells, including stem cells ‘that have had
ex vivo contact with live nonhuman animal cells’ (2).
On the other hand, a second potential barrier to stem-cell
therapy—the matter of histocompatibility and tissue rejec-
tion—has recently been addressed. Induced pluripotent stem
(iPS) cells provide a potentially powerful route for cell thera-
pies based upon autologous, patient-speciﬁc stem cells (3,4).
Most current protocols for iPS cell generation require the
expression of a cohort of transcription factors (TFs) in the
target cell, either by gene transfer (5–7), direct protein intro-
duction (8,9), chemical agents (10–12) or synthetic modiﬁed
mRNA (13) to reprogram terminally differentiated somatic
cells into iPS cells (3,4,14). Although iPS cells exhibit a
unique gene expression signature (15), they resemble embryo-
nic stem (ES) cells in many respects, including the expression
of pluripotency markers, the ability to differentiate into cell
types that represent all three germ layers, and to contribute
to chimerism and teratoma formation in mice. Accordingly,
iPS cells hold promise for cell replacement therapy as well
as for the study of fundamental disease mechanisms, while cir-
cumventing some of the ethical issues associated with the use
of hES cells (16–19).
At least two additional issues remain for iPS cells, including
the need to identify efﬁcient and readily available sources of
starting cells for reprogramming and the development of efﬁ-
cient derivation protocols that do not require viral vectors.
There are several ongoing efforts to develop such viral-free
protocols, but current approaches exhibit relatively low iPS
cell derivation efﬁciencies (8–13). While human dermal ﬁbro-
blasts (HDFs), hair follicle cells, blood cells and adipose stem
cells have all been evaluated, recent primary derivation studies
indicate the relatively inefﬁcient generation of iPS cells (e.g.
 0.2–0.001% efﬁciency) and the need for prolonged deri-
vation times, encompassing 10 days to 4 weeks
(3,4,11,14,20–26). However, an intriguing observation from
iPS cell derivation protocols that have compared somatic
cell types of different developmental ages is that younger
cell types appear to exhibit more efﬁcient reprogramming to
the iPS cell state (14,27).
From a clinical perspective, the most readily accessible
embryonic cells in the body are amniocytes, a heterogeneous
cell population in the amniotic ﬂuid surrounding the develop-
ing fetus that represent cells exfoliated from the embryo and
placenta (28). As a result, amniocytes are developmentally
primitive, undergo rapid proliferation in vivo and in vitro
and are likely to include embryonic progenitor cells (29).
Indeed, small subpopulations of amniocytes have been
suggested to be multipotent (30,31). Studies have used
mesenchymal stem cells in amniotic ﬂuid that are presumably
shed from the placenta to perform autologous fetal tissue
engineering of sternum, trachea, bladder and diaphragm, and
to generate renal and osteogenic tissue (28,31–33). In
addition, an amniocyte subpopulation representing  0.9% of
total amniocytes, termed amniotic ﬂuid-derived stem (AFS)
cells, can be isolated by virtue of their CD117/c-Kit
expression and these cells appear to be multipotent (30). Simi-
larly, iPS cell derivation has recently been reported after the
culture of human amniocytes on mouse feeder cells (34,35).
In an initial study, following long-term culture, human
amniotic ﬂuid-derived cells (hAFDCs) were correctly repro-
grammed to an iPS cell state with efﬁciencies ranging from
0.059 to 1.525% at 6 days post-infection (34), while in a
second study cultured AF skin cells formed iPS colonies
approximately twice as fast and at nearly twice the rate as cul-
tured adult skin cells (35).
It has been hypothesized that amniocytes might be easier to
directly reprogram to the iPS cell state than other available
somatic cell types because of the likely similarity of their tran-
scriptional and epigenetic states to those of early embryonic
cell types (34,35). Over 150 000 second trimester amniocent-
eses are performed annually in the US alone and the extra
amniocytes that are not used for karyotyping, genetic testing
or other analyses are typically discarded (36), making them
potentially available for iPS cell generation. Amniocytes are
autologous to the fetus and semi-allogeneic to each parent,
thereby expanding the potential utility of amniocyte-derived
iPS (AdiPS) cells to other family members. Because of their
early embryonic origin, amniocytes may have accumulated
less genetic damage due to replication errors or somatic
mutation than older cell types, potentially allowing derivation
of iPS cells with improved lifespan and reduced neoplastic
tendency. Based on these potential advantages, we therefore
sought to further optimize this system and to extend its poten-
tial for clinical translation, making use of parallel studies in
both the human and mouse.
Here we report the rapid and efﬁcient generation of human
amniocytes in as few as 5 days in a serum-free system that
employs freshly discarded amniotic ﬂuid cells from a clinical
cytogenetics laboratory. This high efﬁciency of iPS cell gener-
ation appears to reﬂect general properties of amniotic ﬂuid
cells, and not selection for, or reprogramming of known sub-
populations of amniotic ﬂuid cells. To make the derivation
protocol more efﬁcient, we have also used manual picking
of live immunostained iPS cell colonies to simplify their selec-
tive puriﬁcation and expansion. Lastly, of speciﬁc relevance to
future translational applications, it would be a signiﬁcant
advance if one could avoid the xenoculture of human stem
cells on MEFs or animal-derived feeder cells. Interestingly,
AFS cells derived from amniocytes have been reported to
maintain multipotency in the absence of a supporting feeder
layer (30). This observation suggested that amniocytes might
be able to substitute for MEF feeder layers in ES or iPS cell
culture. Thus, we evaluated and established the feasibility of
using mitotically inactivated human and mouse amniocytes
as a source of feeder layers for the propagation of undifferen-
tiated pluripotent iPS and ES cells. This latter innovation may
further advance the clinical utility of human iPS and ES cell
systems.
RESULTS
Reprogramming of mouse amniocytes
To explore the reprogramming of amniocytes in depth, we ﬁrst
focused on mouse amniocytes, which are more reproducibly
obtained than human amniocytes and uniform in genetic back-
ground. In 14 separate experiments, performed according to
the protocol summarized in Figure 1A–C (and detailed in
Materials and Methods), mouse amniocyte cultures transduced
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absence of a feeder layer formed multiple ES cell-like colonies
on day 5 post-infection (Fig. 2A and E, Table 1). When these
colonies were further cultured, prior to transfer to feeder layers
for long-term propagation, there was a notable increase in
colony number between days 5 and 7. Mouse amniocyte cul-
tures transduced with only Klf4 and c-Myc also exhibited mul-
tiple colonies with ES cell morphology, but not until day 7
post-infection (Fig. 2A and I, Table 1). All other binary com-
binations of TFs failed to generate such colonies in six differ-
ent experiments. In addition, prolonged culture of amniocytes
in numerous experiments did not result in the formation of iPS
cell-like colonies.
The four-factor- and two-factor-derived mouse amniocyte
colonies, provisionally termed 4-mAdiPS and 2-mAdiPS
cells, respectively, resembled mouse ES (mES) cells. They
could be maintained and passaged multiple times using a stan-
dard mES cell protocol with mitotically inactivated MEF
feeder layers (MEF feeders) and mES cell medium (see
Materials and Methods). In addition, when mouse amniocyte-
derived colonies were cultured in mES cell medium on low
adhesion plates without feeder cells and in the absence of
LIF or bFGF for 3 to 7 days, embryoid bodies (EBs) formed.
The expression of pluripotency markers by mouse
amniocyte-derived colonies was ﬁrst assessed by histochem-
ical staining for alkaline phosphatase (AP) activity and by
immunocytochemistry for Oct4 and SSEA-1 (Fig. 2A–L).
Similar to mES cells, both 4-mAdiPS and 2-mAdiPS cell colo-
nies were positive for AP activity and immunoreactive for
Oct4 and SSEA-1. Using live immunostaining for SSEA-1,
putative mouse iPS colonies were selectively picked and
enriched for further characterization. RT–PCR and western
blot analyses further conﬁrmed the expression of SSEA-1
and other pluripotency markers in the immunoselected iPS
cell populations (Fig. 2M and N). Speciﬁcally, analysis of
RNA isolated from induced amniocyte cultures that contained
signiﬁcant numbers of colonies revealed abundant levels of
Oct4, Nanog and Sox2 transcripts, comparable with the
levels detected in G4 mES cells. Oct4 protein expression
was conﬁrmed by western blot. Both untreated amniocytes
and MEFs were excluded as sources of signiﬁcant marker
expression. These data strongly suggest that the amniocyte-
derived induced colonies represent iPS cells.
4-mAdiPS and 2-mAdiPS cells are pluripotent
To further assess the pluripotency of mAdiPS cells, two types
of differentiation experiments were performed. In the ﬁrst
type, 4-mAdiPS cells were injected subcutaneously into
severe combined immunodeﬁciency (SCID) mice and the ter-
atomas that formed after 3 weeks (n ¼ 12) were analyzed by
H&E staining and immunohistochemistry to assay for differ-
entiation markers speciﬁc to cell types from the three germ
layers (Fig. 2O–T). Teratomas derived from 4-mAdiPS cells
demonstrated glandular epithelium and smooth muscle differ-
entiation, and expressed alpha-fetoprotein (AFP), smooth
muscle actin (SMA) and neuroﬁlament (NF), indicative of
endodermal, mesodermal and ectodermal differentiation,
respectively. In the second type of experiment, both
4-mAdiPS and 2-mAdiPS cells, allowed to differentiate in
vitro in culture for 2 weeks in the absence of LIF, revealed
immunocytochemical results similar to those observed for ter-
atoma formation, indicating the differentiation of endodermal,
mesodermal and ectodermal cell types (Fig. 1U–W).
mAdiPS cells can be rapidly and efﬁciently derived from
mouse amniocytes
Having determined that the mAdiPS colonies satisﬁed several
criteria for iPS cells, we next determined the efﬁciency of iPS
cell colony formation from mouse amniocytes, compared with
the efﬁciency of iPS cell colony formation from MEFs
(Table 1). MEFs transduced with four factors initially
formed colonies with an efﬁciency of  0.1% (115+11 colo-
nies per 10
5 MEFs; mean+SEM; n ¼ 14 experiments) at day
5 post-infection. In contrast, mouse amniocytes formed 704+
125 and 2016+560 colonies per 10
5 amniocytes at days 5 and
7, respectively, for a nominal efﬁciency at day 7 of  1.4%.
When assayed for AP activity or Oct4 immunoreactivity,
about one-third of the colonies were uniformly positive for
each marker. Since other experiments revealed these markers
to largely overlap, the overall efﬁciency of pluripotent
colony formation (by this and other criteria described below)
is on the order of 1.4% × 1/3 or  0.5%. These data also indi-
cate that the induction of pluripotency in mouse amniocytes is
signiﬁcantly faster (5 days post-infection) relative to that
reported for other cell types such as MEFs
(3,4,11,14,20–26). Similar induction efﬁciencies were also
observed for pluripotent colony formation from mouse amnio-
cytes when just Klf4 and c-Myc were used. However, a lag of
two additional days for the emergence of 2-mAdiPS cells com-
pared with 4-mAdiPS cells was observed. No colonies
Figure 1. Reprogramming protocol and infection efﬁciency of mouse and
human amniocytes. (A) Mouse or human amniocytes were plated (day 23)
in the absence of feeder layers and infected (day 0) with four (Oct4, Sox2,
Klf4, c-Myc) or two (Klf4, c-Myc) retroviral vectors, with colonies emerging
by 5 days (four factors, mouse and human) or 7 days (two factors, mouse)
post-infection. Colonies were picked on day 9 via live immunostaining and
transferred to feeder layers. (B) Phase image of cultured mouse amniocytes
5 days after plating. (C) The efﬁciency of retroviral infection of cultured
amniocytes was .90% as reﬂected by retroviral GFP reporter expression 2
days post-infection. (D) A single primitive hAdiPS cell colony on day 5 post-
infection (scale bars, 200 mm).
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factors and analyzed out to 9 days post-infection.
Amniotic ﬂuid stem cells do not preferentially contribute
to mAdiPS cell generation
The ﬁnding of endogenous stem cells in amniotic ﬂuid (30)
suggests a potential explanation for the relative efﬁciency of
iPS cell induction. To test the idea that these cells are
simply being selected for, or are already partly
re-programmed, c-Kit-positive mouse amniotic ﬂuid-derived
cells, proposed to represent AFS cells (30), were isolated by
ﬂow cytometry or by magnetic separation (see Materials and
Methods), and either cultured without further treatment or sub-
jected to reprogramming. The efﬁciency and temporal emer-
gence of iPS colonies was no greater or faster for c-Kit
enriched cultures than for control amniocyte cultures (0.13%
efﬁciency of mouse AdiPS cell generation by day 5 for both
c-Kit enriched and non-c-Kit enriched cells). These data
suggest that c-Kit-positive AFS cells do not contribute prefer-
entially to the origin of mAdiPS cells. Similarly, to investigate
the potential contribution of rare Oct4
+ cells present in amnio-
tic ﬂuid (30,34), we applied our iPS cell induction protocol to
amniocytes from a transgenic Oct4-GFP reporter mouse strain
(37). Although eventually many of these colonies express
GFP, no immediate enrichment for, or recruitment of GFP
+
cells in colonies was observed at 5 days post-infection.
These results argue against a selective contribution of c-Kit
+
or Oct4
+ amniocyte subpopulations to mAdiPS cell deri-
vation.
Human AdiPS (hAdiPS) cells can be rapidly derived from
fresh and long-term cultured human amniocytes
We next sought to extend our observations on the generation
of mAdiPS cells from mid-gestation mouse amniocytes to
second trimester human amniocytes. Amniocytes were col-
lected from three individuals and subjected to reprogramming
within 2 weeks of initial plating, as soon as the cells were
released from the clinical cytogenetics laboratory. Human
amniocytes transduced with four factors demonstrated the
same rapid and efﬁcient formation of hAdiPS cell colonies
Figure 2. mES, 4-mAdiPS and 2-mAdiPS cells exhibit similar morphology, gene expression and pluripotency. (A–L) Similar morphology, alkaline phophatase
histochemical staining, Oct4 and SSEA-1 immunoreactivity for R1 mES, 4-mAdiPS and 2-mAdiPS cells (scale bars, 50 mm). (M) RT–PCR analysis shows
similar Nanog, Oct4 and Sox2 expression in mES, 4-mAdiPS and 2-mAdiPS cells. (N) Western-blot expression of Oct4 in 4-mAdiPS cells at the expected
40 kDa size. (O) Teratoma derived from 4-mAdiPS cells injected into SCID mouse. (P and Q) Differentiation of histologically distinct tissue types in teratomas
derived from 4-mAdiPS cells injected into SCID mice, assessed by H&E staining, demonstrates glandular and smooth muscle differentiation (scale bars,
200 mm). (R–T) Positive immunostaining for AFP, SMA and NF in teratomas derived from 4-mAdiPS cells injected into SCID mice. (U–W) 2-mAdiPS
cells differentiated in vitro for 7 days exhibit similar immunoreactivity for AFP, SMA and NF (scale bars, 100 mm). mES, mouse embryonic stem cells;
Alk. Phos., alkaline phosphatase; mAmnio, mouse amniocytes; MEFs, mouse embryonic ﬁbroblasts; AFP, alpha-fetoprotein; SMA, smooth muscle actin;
NF, neuroﬁlament.
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5 human
amniocytes) as seen with mouse AdiPS cells. From one indi-
vidual alone, 18 clonal hAdiPS cell lines were obtained and
characterized (Fig. 3). These colonies closely resembled hES
cell colonies in terms of morphology (Fig. 3A and F), immu-
nostaining for OCT4, SSEA-4, TRA-1-60 and TRA-1-81
(Fig. 3B–E, G–J), and AP reactivity (data not shown). Karyo-
type analysis of one clonal hAdiPS cell line demonstrated a
normal human male karyotype (Supplementary Material,
Fig. S1A).
Gene expression analysis of hAdiPS cells
RNA expression of OCT4, SOX2, GDF3, DNMT3B and REX1
was conﬁrmed in presumptive hAdiPS cells by RT–PCR
(Fig. 3K). In contrast, primary human amniocytes expressed
lower levels of OCT4 and did not express SOX2, GDF3,
DNMTB3B or REX1, and MEFs did not express any of these
genes at detectable levels. As an additional test of the pluripo-
tency of AdiPS cells, we performed microarray gene
expression analyses with RNA isolated from live, SSEA-4,
TRA-1-60 or TRA-1-81 immunostained hAdiPS cells, and
also from hES cell colonies and primary amniocytes. Based
on the expression levels of 11328 genes, hAdiPS cells demon-
strated greater similarity in their gene expression proﬁles
compared with control H1 hES cells than with human amnio-
cytes (Figs 3L and 4A and B, Supplementary Material,
Fig. S3). A correlation matrix comparing genome-wide
mRNA expression data between hES cells, hAdiPS cells and
human amniocytes demonstrated a correlation coefﬁcient
(r
2) of 0.98–0.99 between hES and hAdiPS cells, compared
with 0.82–0.85 between human amniocytes and hES cells,
and 0.82–0.85 between human amniocytes and hAdiPS cells
(Supplementary Material, Fig. S3). Furthermore, methylation
sequence analysis of genomic DNA for the endogenous
OCT4 and NANOG promoter regions demonstrated
demethylated patterns for hAdiPS cells comparable with
those observed in hES cells (Fig. 3M, Supplementary Material,
Fig. S2). Interestingly, of the 12 amniocyte lines assayed, the
proportion of methylation sensitive sites in the OCT4 promoter
that were actually methylated was variable and in all cases less
than 50%; this suggests some pre-existing epigenetic resem-
blance to the pluripotent state. Nonetheless, hAdiPS cells
resemble hES cells much more closely than they resemble
amniocytes in their gene expression proﬁle, and in the
demethylation pattern of two key pluripotency genes. These
results support the conclusion that human amniocytes can be
effectively reprogrammed to a pluripotent state.
hAdiPS cells are pluripotent and can differentiate into
endoderm, mesoderm and ectoderm
To further establish the pluripotency of hAdiPS cells, we next
examined their differentiation capacity. Under differentiation
conditions, cultures of hAdiPS cells (Fig. 5A–C) and
hAdiPS cell-derived EBs (Fig. 5D–F) demonstrated ectoderm,
endoderm and mesoderm formation, as reﬂected by AFP,
SMA and NF expression, respectively. In addition, we were
able to efﬁciently generate teratomas 7 to 8 weeks after
hAdiPS cells were injected into hind leg muscles of SCID
mice (see Materials and Methods). Analysis of the cellular
composition of these teratomas, determined by ﬁxation, cryo-
sectioning and H&E staining, demonstrated histologically dis-
tinct types of tissue that represent the three germ layers
(Fig. 5G–I). Consistent with the histological ﬁndings, immu-
nohistochemistry of these tissue sections revealed positive
immunostaining for AFP, SMA and NF (Fig. 5J–L). Collec-
tively, the above results indicate that, consistent with other
reports (34,35), human amniocytes can be reprogrammed to
functional iPS cells at high efﬁciency.
Amniocytes can function as feeder cell layers for mES, hES
and hAdiPS cells
Our results showing that amniocytes can be efﬁciently repro-
grammed to a pluripotent state, coupled with the observation
that AFS cells do not require a feeder layer for self mainten-
ance (30), prompted us to consider whether amniocytes them-
selves might function as feeder layers for mouse and human
ES and AdiPS cells. To test this hypothesis, we ﬁrst plated
R1 mES cells that contained an Oct4-GFP reporter gene on
a monolayer of freshly harvested or previously passaged
E13.5 mouse amniocytes (amniocyte feeders) that had been
mitomycin-treated at a density of 10
5 amniocytes per
1.76 cm
2 (see Materials and Methods). We then propagated
the mES cell cultures for 20–25 serial passages over 75
days. During this time, mES cells maintained on mouse
amniocyte feeder layers exhibited colony morphology associ-
ated with an undifferentiated ES cell state, and behaved indis-
tinguishably from mES cells maintained in parallel on MEF
feeders. At the end of 75 days, we examined the expression
of pluripotency markers in mES cells maintained on amnio-
cytes by immunocytochemistry, RT–PCR and qRT–PCR, as
well as by their capacity for differentiation into derivatives
of all three germ layers, and for germline competent mouse
chimera formation (Fig. 6). Colonies of R1 mES cells
Table 1. Efﬁciency and latency of AdiPS cell generation from mouse and
human amniocytes
No. of factors
(species)
Days
post-infection
No. of colonies per 10
5 treated cells
a
Amniocytes MEFs
Four factors
(mouse)
5 704+125 (32% AP
+,
34% Oct4
+)
115+11
Four factors
(mouse)
7 2016+560 89+12
Two factors
(mouse)
5n d n d
Two factors
(mouse)
7 674+59 nd
Four factors
(human)
5 2916+8 115+11
aData are shown as mean+SEM from 14 experiments. Mouse amniocytes or
MEFs were transduced with retroviral vectors expressing either four or two
factors (Oct4, Sox2, Klf4, c-Myc; or Klf4, c-Myc), and assayed for colony
formation at the day post-infection indicated. For four-factor day 5 and
two-factor day 7 protocols, the % AP and % Oct4-positive colonies are shown
in parentheses.
MEFs, mouse embryonic ﬁbroblasts; nd, no colonies detected; AP
+, alkaline
phosphatase positive; Oct4
+, Oct4 positive.
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chemical staining, BrdU labeling, Oct4-GFP reporter
expression and Oct4 immunostaining (Fig. 6A–D). These
results were indistinguishable from the results observed for
colonies of mES cells maintained and passaged under compar-
able conditions on MEF feeders (data not shown). Further-
more, mES cells cultured on mouse amniocyte feeders
continued to express Oct4, Nanog and Sox2 at levels compar-
able to those observed for mES cells on MEF feeders by both
RT–PCR (Fig. 6G) and by qRT–PCR (data not shown).
Moreover, mES cells cultured on mouse amniocytes and
allowed to differentiate for 7–14 days in vitro exhibited
marker expression for NF and SMA (Fig. 6E and F). mES
cells cultured on amniocytes also exhibited efﬁciencies of
chimera formation (13/35 versus 4/10, for mES cells main-
tained on amniocyte versus MEF feeders, respectively),
percent of mES cell coat color contribution and rate of germ-
line transmission, comparable to those maintained on MEF
feeders (Fig. 6H and data not shown). Based on these speciﬁc
analyses, mouse amniocytes and MEFs appear to function
equivalently as feeders for mES cell culture.
Next, since the transmission of viruses and other infectious
agents between animal-derived feeders and hES cells is a
potential obstacle to human cell therapy, we tested the
ability of g-irradiated human amniocytes (human amniocyte
feeders) to maintain H1 hES cells and hAdiPS cells in an
undifferentiated state. In this case, after passage of stem
cells for 21 days, both hES cells (Fig. 6I–K) and hAdiPS
(Fig. 6O–T) cells retained OCT4, SSEA-4 and TRA-1-81
expression by immunostaining, and exhibited normal differen-
tiation in EB (Fig. 6L–N) and teratoma formation (data not
shown) after 7 and 56 additional days, respectively. In
addition, H1 hES cells retained a normal karyotype under
these culture conditions (Supplementary Material, Fig. S1B).
These results indicate that human amniocytes can function
as feeder layers for hES and hAdiPS cell culture.
DISCUSSION
This work describes an amniocyte-based stem-cell derivation
and culture system that has potential utility for the transla-
tional application of human stem-cell-based therapies
(Fig. 7). This system has several features that potentially
address currently problematic aspects associated with existing
approaches to stem-cell therapy. The advances tendered by
this work include: (i) the derivation of both iPS and feeder
cells from a single pool of donor amniocytes, pre-screened
for pathogenic human viruses; (ii) the avoidance of exposure
to animal products (serum, feeder cells); (iii) the use of
live cell immunostaining for efﬁcient selection of repro-
grammed iPS cell colonies; and (iv) the previously described
enhanced reprogramming efﬁciency which human amniocytes
exhibit (34,35).
Figure 3. hES and hAdiPS cells exhibit similar morphology and gene expression. (A–J) Similar morphology and OCT4, SSEA-4, TRA-1-60 and TRA-1-81
immunoreactivity for H1 hES cells and hAdiPS cells (scale bars, 100 mm). (K) Transcripts for OCT4, SOX2, GDF3, DNMT3B and REX1 are expressed at com-
parable levels in hES and hAdiPS cells. (L) Microarray analysis of hAdiPS cell gene expression compared with H1 hES cells demonstrating 0.99 correlation as
opposed to 0.82 for human amniocytes relative to H1 hES cells. (M) Bisulﬁte-treated PCR-ampliﬁed sequence of the promoter regions of OCT4 and NANOG.
Open and closed circles indicate unmethylated and methylated CpGs. hES, human embryonic stem cells; hAmnio, human amniocytes; MEFs, mouse embryonic
ﬁbroblasts.
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ponents of the system (i.e. iPS cells and their supporting feeder
cells) originate from a single cell source. If these cells orig-
inate from a future recipient, then the transferred cells, and
any feeder cells that might be co-transferred to a recipient,
either inadvertently or on purpose, will be autologous to the
recipient. In principle, this would further obviate the potential
for an immune reaction. The potential availability of human
amniocytes, which can be banked and which are considered
a discarded tissue by most institutional review boards
(IRBs), thus offers the opportunity for the culture of human
stem cells and feeders that are both autologous to the intended
recipient. While the banking of fetal amniocytes for future use
may seem logistically complex, it should be noted that
banking of umbilical cord blood cells for similar purposes
has already been implemented clinically.
We show that mitotically inactivated amniocytes can serve
as feeder layers for the co-culture and self-renewal of both
human iPS and ES cells (Fig. 7), thereby circumventing the
need for MEF feeders and the accompanying concerns about
xenoculture and resultant zoonosis. The transfer of human
stem cells that have been cultured with nonhuman animal
cell feeder layers and then transplanted into a human recipient
falls under the FDA deﬁnition of xenotransplantation, whereby
any ‘human body ﬂuids, cells, tissues, or organs that have had
ex vivo contact with live nonhuman animal cells, tissues, or
organs’ are themselves xenotransplant materials (38,39). The
concern regarding xenotransplantation is the potential for
transmission of recognized, or as yet unrecognized, infectious
agents from animals to humans (38). Because it avoids the use
of ‘animal cells, tissues or organs,’ our iPS cell derivation and
culture system would not involve xenotransplantation. Our
hAdiPS cell derivation protocol also avoids the use of fetal
bovine serum by employing KOSR, a serum-free culture
medium (see Materials and Methods). In addition, the
human iPS cell lines derived here originate from human
amniotic ﬂuid cells that are already routinely screened for
evidence of infectious agents including hepatitis, human
immunodeﬁciency virus and rubella. The use of an individ-
ual’s own cells and tissues without exposure to animal cells,
and after screening for human infectious agents, should help
obviate concerns about zoonosis associated with the use of
MEF feeders, and about latent viral infection. These features
Figure 4. (A) Dendrogram and (B) heatmaps showing relationship between two independent samples of each of hES cells, hAdiPS cells and human amniocytes.
The expression values within heatmaps represent the fold difference of expression from the ES cell lines calculated by the logarithm (base 2) of the ratio between
the expression level for a gene between the average expression of the ES cell lines for that particular gene. Heatmaps were prepared using unsupervised hier-
archical clustering.
Figure 5. hAdiPS cells demonstrate pluripotency. (A–C) hAdiPS cells differ-
entiated in culture for 14 days exhibit subpopulations of cells immunoreactive
for AFP, SMA and NF. (D–F) Similar immunoreactivity is observed when
cryosections of EBs from hAdiPS cells are analyzed (scale bars, 100 mm).
(G–I) Analysis of teratomas derived from hAdiPS cells injected in SCID
mice shows differentiation of histologically distinct tissue types such as gland-
ular tissue (endoderm), muscle tissue (mesoderm) and neuroepithelial tissue
(ectoderm), respectively (scale bars, 100 mm). (J–L) Positive immunostaining
for AFP, SMA and NF in teratomas derived from hAdiPS cells injected into
SCID mice (scale bars, 50 mm). EBs, embryoid bodies; AFP, alpha-
fetoprotein; SMA, smooth muscle actin; NF, neuroﬁlament; SCID, severe
combined immunodeﬁcient mice.
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diseases. Another obvious limitation of many current iPS
cell derivation approaches is the use of viral vectors for efﬁ-
cient derivation. However, research in many laboratories is
directed towards developing efﬁcient, viral-free derivation
protocols. Although we employed retroviral vectors in the
current study, we found it possible to avoid the use of
serum, both in iPS cell generation and even in reprogramming
vector preparation. Collectively, these improvements should
promote clinical translation by improving the overall efﬁ-
ciency of reprogramming from an available clinical source,
and by establishing the feasibility of using the same individ-
ual’s amniocytes as feeders.
It should be noted that other human feeder layers and
feeder-free culture media have been described, including
deﬁned and serum-free media that support undifferentiated
hES cell growth for up to 10 passages (40,41). However,
hES cells maintained in feederless systems can eventually
become karyotypically unstable (42,43). Recently, HDFs
have been shown to serve as autologous feeders for hiPS
cells, but HDF-derived iPS cells and HDF-derived feeders
are limited by prolonged derivation times and the fact that
not all HDF cell lines efﬁciently support hES or hiPS cell
growth (44). Nonetheless, the HDF and amniocyte systems
may prove complementary, as the former would be useful
for the vast majority of who did not have the opportunity to
have their amniocytes banked. However, going forward, the
large individuals number of amniocenteses performed in the
USA and other industrialized nations could provide a practical
source for banked amniocytes and for AdiPS cells and feeder
cells for cell therapy applications.
Compared to other somatic cell types, amniocytes offer
several potential advantages for the generation of iPS cells.
Mouse and human amniocytes provide a source of cells that
permit the generation of iPS cells with a signiﬁcantly higher
efﬁciency, by more than 10-fold, relative to MEFs or HDFs.
By our most conservative estimate,  0.5% of mouse or
human amniocytes can be reprogrammed to a pluripotent
state, as further conﬁrmed by AP and Oct4 expression and
by subsequent differentiation experiments (EB formation, ter-
atoma analysis), microarray gene expression and methylation
analysis of human iPS cell genomic DNA. In contrast, the efﬁ-
ciencies reported for adult human ﬁbroblasts, MEFs, blood
cells, adipose stem cells and keratinocytes are: 0.01, 0.001,
0.001, 0.2 and 0.002%, respectively (4,14,20,23,26,45).
Thus, human amniocytes are a highly efﬁcient target cell for
iPS cell derivation. Indeed, results from this and other
studies (34,35) indicate that amniocytes represent the most
rapidly reprogrammed cell population by primary infection
yet described, with a latency of  5–6 days, compared with
about 10 days to induce iPS cell colonies from keratinocytes
(20) and 2 weeks or more from MEFs (14,20). Lastly, our
studies in the mouse system suggest that just two factors
(Klf4 and c-Myc) are sufﬁcient to initiate pluripotency, and
the 2-factor mouse AdiPS cells were able to differentiate
into all three germ layers. No other reprogramming protocol
that we are aware of permits the omission of Oct4 in iPS
cell derivation. Although the use of Klf4 and c-Myc, two
Figure 6. Mitotically inactivated amniocytes function as feeder layers for mES, hES and hAdiPS cells. (A and B) Mitomycin C-treated mouse amniocytes func-
tion as feeder layer for R1 mES cells. After 10 passages (30 days) in culture, mES cell colonies demonstrate AP activity and BrdU labeling. (C and D) Oct4-GFP
reporter ﬂuorescence and Oct4 immunostaining of mES colonies cultured for 30 days on amniocyte feeders. (E and F) NF and SMA immunostaining after 7 and
14 days of in vitro differentiation, respectively. (G) RT–PCR analysis of Oct4, Nanog and Sox2 expression in early (E, ,3) and late (L, .10) passage mES cells
maintained on MEFs or mouse amniocytes. Controls (∗) are feeders without mES cells. (H) Germline competent chimera from blastocyst injection of mES cells
maintained for 50 days (15 passages) on mouse amniocyte feeder layer. (I–K) OCT4, SSEA-4 and TRA-1-81H1 immunoreactivity in hES cells cultured for 21
days (six passages) on g-irradiated human amniocytes. (L–N) AFP, SMA and NF immunostaining after EB differentiation of H1 hES cells cultured on
g-irradiated human amniocytes. (O–T) g-irradiated human amniocyte feeder layers support growth and self-renewal of hAdiPS cells derived from the same
amniocytes. After 21 days (ﬁve passages) in culture, hAdiPS cell colonies demonstrate AP activity and OCT4, SSEA-4, TRA-1-60 and TRA-1-81 expression
by immunocytochemistry. mES and hES cells, mouse and human embryonic stem cells; AP or Alk. Phos., alkaline phosphatase; BrdU, bromodeoxyuridine;
Amnios, mouse amniocytes; MEFs, mouse embryonic ﬁbroblasts; EP, early passage; LP, late passage; AFP, alpha-fetoprotein; SMA, smooth muscle actin;
NF, neuroﬁlament. Scale bars: 100 mm.
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on these two factors, similar two factor experiments will be of
interest in human amniocytes.
Why are mouse and human amniocytes so readily repro-
grammed? One possible explanation relates to the notion
that embryonic cells more closely resemble the pluripotent
state in terms of their transcriptional and chromatin states
than other somatic cell types. Recent work by Hochedlinger
and colleagues (27) using a secondary system to generate
iPS cells in the context of hematopoiesis clearly demonstrates
that the differentiation state of a cell strongly impacts both
the efﬁciency and kinetics of reprogramming. In particular,
progenitor stages for various hematopoietic lineages show
higher re-programming efﬁciencies than more differentiated
stages (27). Thus, while human foreskin ﬁbroblasts and
MEFs have been used for iPS cell induction and represent
perinatal and embryonic cell types, respectively, amniocytes
can be isolated as early as 15 weeks in the human (36)
and at E8.5 in the mouse (our observations). At these
early developmental stages, some embryonic cells that are
shed into the amniotic ﬂuid may retain substantial multipo-
tency, and may even approximate the pluripotent stem-cell
state.
Thus, the observation that amniocytes are so readily repro-
grammed may partly reﬂect their embryonic origin. These
cells may already possess a partly pluripotent transcriptional
or epigenetic state and be more readily reprogrammed than
adult cell types. In this regard, it is notable that while
hAdiPS cells demonstrate a highly concordant transcriptional
expression proﬁle with hES cells (r
2 ¼ 0.98–0.99), non-
reprogrammed amniocytes also exhibit signiﬁcant
concordance with hES and hAdiPS cells (r
2 ¼ 0.82–0.85)
(Supplementary Material, Fig. S3). In addition, the donor
amniocyte OCT4 promoter methylation pattern is heteroge-
nous and incomplete (Fig. 3M). Although we were unable to
show preferential reprogramming of endogenous
Oct4-expressing amniocytes, the incompleteness of Oct4 pro-
moter methylation in amniocytes could facilitate conversion to
the demethylated state that characterizes pluripotency. Emer-
ging studies imply that the epigenetic memory of speciﬁc
donor cell types may restrict the subsequent differentiation
potential of derived iPS cells (46–48). For example,
ﬁbroblast-, hematopoietic- and myogenic-derived iPS cells
exhibit distinct transcriptional and epigenetic patterns and
differentiation potential (48). Moreover, iPS cells harbor
DNA methylation signatures characteristic of the donor cell,
which favors differentiation related to the donor cell and
restricts alternative fates (46,48). In contrast, by the criteria
of in vitro EB and in vivo teratoma formation, hAdiPS cells
differentiated into tissues representing all three germ layers
without obvious preference for a single tissue type or germ
layer. The current experiments suggest that amniocytes
could be useful for generating iPS cells that can differentiate
into a range of cell types.
An extension of this view is that pluripotent or multipotent
stem cells already exist within the amniocyte population, and
Figure 7. Patient-speciﬁc stem-cell therapy using human amniocytes in a xenoculture-free, autologous system. In this model, discarded amniocytes are obtained
as a byproduct of routine antenatal screening and can be banked. At an appropriate time, they are cultured and reprogrammed in vitro to become patient-speciﬁc
amniocyte-derived induced pluripotent stem (AdiPS) cells. AdiPS cells may then be maintained and expanded on amniocyte feeder cells from the same patient
and subsequently banked for later use in cell-based directed differentiation or other protocols to generate new tissues.
970 Human Molecular Genetics, 2011, Vol. 20, No. 5that our iPS cell protocol simply selects for, or reprograms, an
existing stem-cell-like population already present in amniotic
ﬂuid. Indeed, such an AFS cell population has been described
(30). However, our results show that culture of non-transduced
amniocytes does not result in colony formation even with
extended culture and more than 30 passages. Similarly,
neither AFS cells nor hAFDCs form teratomas in mice
(30,34), although the requirement for a threshold number of
pluripotent cells for teratoma formation (49) may constrain
the sensitivity of this assay. Nonetheless, enrichment for
amniocytes that express the c-Kit receptor, which operation-
ally deﬁnes AFS cells, does not improve the efﬁciency of
iPS cell induction. Therefore, while our results do not
exclude the possibility that a subpopulation of amniocytes
contributes to the derivation of AdiPS cell colonies, it seems
unlikely that previously described AFS cells in amniotic
ﬂuid (30,34) preferentially do so. Additional work is required
to better understand the heterogeneity of amniocytes and to
assess how the different cell types present in amniotic ﬂuid
inﬂuence the efﬁciency of iPS cell induction.
Our observations on mouse and human amniocytes are gen-
erally in agreement with a recent description of efﬁcient but
variable frequency of hiPS cell derivation using human amnio-
cytes that were subjected to long-term culture (.10 passages)
and morphologic selection after infection, and then grown on
mouse feeder cells (34). Two key differences between these
derivation protocols include the other study’s use of morpho-
logic selection prior to analysis, and of mouse feeder layers
and serum-containing media for iPS cell derivation. These fea-
tures of the other protocol may partly explain the over 25-fold
variation in iPS cell derivation efﬁciency between batches of
amniocytes that were observed in those studies. In contrast,
we employed a serum-free and initially feederless system for
hAdiPS cell derivation, and live cell immunoselection for
rapid colony puriﬁcation, prior to long-term propagation on
feeders (15,25). The use of live cell immuﬂuorescent selection
enabled us to clone stem-cell lines with relative ease, and to
exclude incompletely reprogrammed clones from further
analysis. Lastly, a novel innovation is the ﬁnding that amnio-
cytes that are mitotically inactivated with either mitomycin C
(for mouse) or g-irradiation (for human) appear to function
with high ﬁdelity for the propagation and maintenance of plur-
ipotent, undifferentiated iPS and ES cells. The amniocyte
system thus provides an efﬁcient autologous system for
hAdiPS cell generation and culture that could signiﬁcantly
advance the translational application of stem-cell therapy.
MATERIALS AND METHODS
Amniocyte isolation and other cell sources
Mouse amniocytes were obtained from the amniotic sacs of
C57BL6/J mouse embryos by amniocentesis performed on
pregnant E13.5 wild-type C57BL6/J mice (Charles River Lab-
oratories). Uterine horns of pregnant female mice at day 13.5
p.c. were excised, washed in PBS and the amniotic ﬂuid aspi-
rated with a 27 gauge needle from the amniotic sacs. Typi-
cally,  10
4 amniocytes were obtained in 100 ml of amniotic
ﬂuid per sac ( 0.75–1.0 ml per pooled collection from a
single litter). Mouse amniocyte cells were washed in PBS,
and plated at 10
5 cells/ml in a-MEM (Gibco)/10% heat inac-
tivated FBS (HyClone)/1% Pen-Strep (100 U penicillin and
100 mg streptomycin/ml; deﬁned henceforth as ‘amniocyte
media’) at 378C, 5% CO2. They were passaged twice to elim-
inate contaminating red blood cells and to expand amniocyte
number, and assessed morphologically prior to use. Following
two preliminary passages, fresh or frozen-thawed mouse or
human amniocytes were cultured on 0.1% gelatin (Gibco)
coated tissue culture plates (typically 6-well plates) for 3
days at a plating density of 10
5 amniocytes per 1.76 cm
2. Pas-
saged amniocytes were characterized by a ﬁbroblast-like
appearance and rapid proliferation (Fig. 1A). In some cases,
mouse amniocytes were passaged up to 30 times or stored in
liquid nitrogen, thawed and then subjected to reprogramming.
No signiﬁcant difference was observed in the efﬁciency with
which iPS cells could be established from amniocytes that
were continuously passaged, or frozen and thawed.
Oct4-GFP reporter mice (37) were used for some amniocyte
isolations. In other experiments, separations of mouse c-Kit
immunoreactive amniocytes were performed using MACS
cell separation columns and c-Kit (CD117) antibody conju-
gated to magnetic beads (Miltenyi Biotec) (30). After amniotic
ﬂuid isolation, cells were immediately cultured, maintained
and passaged in vitro following standard cell culture protocols.
Emergence of putative iPS colonies was scored on day 5 post-
infection as described below.
Anonymous samples of discarded human amniocytes were
obtained for hAdiPS cell experiments under Brigham and
Women’s Hospital IRB protocol no. 2006p00149 after  2
weeks (two to four passages) of culture. Mouse R1 and G4
ES cells were from the Samuel Lunenfeld Research Institute
(Mt. Sinai Hosp., Univ. Toronto). Human H1 ES cells were
obtained from the National Stem Cell Bank (WiCell,
Madison, WI, USA). MEFs from E13.5 embryos were
treated with mitomycin C and used as feeders for 4-mAdiPS
and 2-mAdiPS cells, while g-irradiated MEFs were prepared
in house or purchased (Global Stem, Inc.) and used as
feeders for hAdiPS cells. In other experiments, feeder layers
were prepared from mouse and human amniocytes (see
below). Feeder preparation and ES cell culture were per-
formed using standard methods (50,51).
Retroviral infection, AdiPS cell generation and culture
Retroviral infection, iPS cell generation and culture were per-
formed in standard manner as previously described (52). Ret-
roviral particles containing each of the four reprogramming
factors, Oct4, Sox2, c-Myc or Klf4, were generated using stan-
dard retroviral production protocols, employing the pMXs ret-
roviral plasmids (53) purchased from Addgene (Cambridge,
MA, USA). 293T cells were plated in DMEM with 10%
FBS (GIBCO) until 30–40% conﬂuency; viral vectors were
then transfected using FuGENE 6 (Roche). Forty-eight hours
after transfection, media containing viral particles was har-
vested and used for infection of amniocyte cultures with the
addition of 6 mg/ml polybrene (Millipore). Target cell
MEFs, mouse amniocytes and human amniocytes were cul-
tured in a feederless system and transduced with two-, three-
and four-factor combinations of pMXs retroviral vectors for
Oct4, Sox2, Klf4 and c-Myc (Addgene, Inc.) (4,14,52), and
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tocol involved using subconﬂuent cultures of mouse or human
amniocytes (70% conﬂuency) that were infected with
pluripotency-inducing retroviral vectors in viral media
[DMEM/10% FBS for mouse cultures; for human amniocytes,
hES media containing 20% KnockOut
w Serum Replacement
(KOSR, Invitrogen, Inc.) instead of FBS] on day 3 (Fig. 1A
and B). The retroviral vectors for Oct4, Sox2, c-Myc and
Klf4 or combinations thereof were added to the amniocyte cul-
tures for 48 h. The media were then changed back to amnio-
cyte media (see Amniocyte isolation and other cell sources
section) with continued culture in a feederless system until
the emergence of the ﬁrst morphologically distinct cell colo-
nies. By day 5 post-infection (four factors, with mouse or
human amniocytes) or day 7 post-infection (two factors with
mouse amniocytes) in culture, colonies resembling ES cell
colonies began to appear (Fig. 2A, E, I, Table 1). By 5–7
days post-infection, emerging colonies were manually picked
(see below) and transferred onto feeder layers. 4-mAdiPS
and 2-mAdiPS and mES cells were cultured on mitomycin
C-treated MEF feeders in DMEM (Gibco)/10%FBS
(HyClone)/LIF at 10
7 units per ml (Millipore)/0.1 mM b-ME
(Sigma-Aldrich) (henceforth deﬁned as ‘mouse ES cell
media’), while hAdiPS and hES cells were cultured on
g-irradiated MEF feeders in 80% DMEM-F12 (Gibco)/20%
KnockOut
w Serum Replacement (KOSR, Gibco)/1 mM
L-glutamine (Gibco)/0.1 mM b-ME (Sigma-Aldrich)/4 ng/ml
bFGF (Invitrogen) (henceforth deﬁned as ‘human ES cell
media’). AdiPS cell cultures were propagated using standard
protocols.
Colony picking
Since not all emergent colonies likely represent iPS cell colo-
nies by the criterion of pluripotency marker expression, puta-
tive mAdiPS cell colonies were manually picked via live
immunostaining for SSEA-1 (25). Primitive mAdiPS cells
were then transferred to MEF feeders for continued culture
(52). For hAdiPS cells, live immunostaining was performed
with TRA-1-60. hAdiPS cell colonies were also manually
picked and transferred to MEF feeders for continued culture.
Such manually picked colonies were used for RNA extraction
and microarray analysis to minimize any contribution from the
underlying feeder cells or from incompletely reprogrammed
amniocytes. Once the identity of the picked colonies was
further veriﬁed by immunocytochemistry and RT–PCR analy-
sis, these clones were expanded on MEF feeders in human ES
cell media. Expanded clones were then additionally character-
ized by differentiation assays, RT–PCR and qRT–PCR, and
karyotypic analysis (see below).
RNA isolation, RT–PCR and microarray analyses
hAdiPS cell colonies that were live stained for SSEA-4 and
TRA-1-60 were individually picked to minimize feeder con-
tamination, and to optimize selection for completely
re-programmed colonies. They were pooled and RNA was iso-
lated with a Qiagen kit (Valencia, CA, USA); RNA from ES
cell colonies was isolated in parallel. RT–PCR analyses
were performed using primers and assay conditions listed in
Supplementary Material, Table S1. Microarray expression
analyses were carried out using Illumina Human WG6 Bead-
Chips (Children’s Hospital Boston Microarray Core Facility
supported by NIH-P50-NS40828 and NIH-P30-HD18655).
Data analyses were performed by normalizing the gene
expression data using the lumi Bioconductor package in the
statistical language R and by clustering relative gene
expression to assess the expression proﬁles of the different
samples. Each microarray was individually normalized by
quantile normalization provided by the lumi package.
Quality control was performed within each sample group by
examining pairwise correlations. After normalization, probes
that were deemed to have no signal by the lumi package
across all the human samples were excluded from further cal-
culation. The expression of each gene was calculated from the
remaining probes by ﬁrst mapping each probe to its corre-
sponding gene (using the lumiHumanIDMapping package)
and then by averaging all probes that corresponded to a par-
ticular gene. The expression values within heatmaps represent
the fold difference of expression from the ES cell lines calcu-
lated by the logarithm (base 2) of the ratio between the
expression level for a gene between the average expression
of the ES cell lines for that particular gene. For producing
the heatmaps, unsupervised hierarchical clustering was used
based on the heatmap.2 function in the gplots package with
average linkage.
Bisulﬁte sequencing of genomic DNA
Genomic DNAs from the different experimental groups of
cells (MEFs, human amniocytes, H1-hES cells and hAdiPS
cells) were isolated using the DNAeasy tissue kit (Qiagen).
Puriﬁed DNA was treated with bisulﬁte to convert cytosine
to uracil using the EpiTect kit (Qiagen). PCR ampliﬁcation
of the human OCT4 and NANOG promoter regions was under-
taken using published primers (54). The PCR products were
gel puriﬁed, cloned into TOPO TA vectors (Invitrogen) and
sequenced using the forward and reverse M13 primers (Biopo-
lymers Sequencing Core Facility at Harvard Medical School
and Children’s Hospital Boston Sequencing Core Facility).
Methylation patterns of the cloned sequences were analyzed
using CpG viewer software (Fig. 3M).
Karyotypic analysis
Cytogenetic analyses were performed on hAdiPS and hES
cells. All of the hAdiPS cell samples and the majority of the
hES cell samples demonstrated normal karyotypes. Analyses
were performed by Cell Line Genetics, Inc. (Madison, WI,
USA).
Alkaline phosphatase staining and immunohistochemistry
Cultures of presumptive AdiPS cells were ﬁxed in 4% parafor-
maldehyde (PFA)/4% sucrose and processed for immunostain-
ing. Commercial antibodies for mouse Oct4, SSEA-1 and for
human OCT4, SSEA-4, TRA-1-60 and TRA-1-81 (Abcam),
and histochemical reagents for alkaline phosphatase activity
(Sigma Aldrich) were used for marker studies. Differentiation
of AdiPS cells was evaluated by immunostaining with
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derm) and alpha SMA (mesoderm) (Abcam). Primary and sec-
ondary antibody immunohistochemistry was performed
according to standard protocols. Controls included omission
of primary or secondary antibody, and comparison of differen-
tiated and undifferentiated cells.
EB, teratoma and chimera generation
EBs were generated by replacing ES medium with medium
consisting of 68% DMEM-F12/1% Pen/Strep (Gibco)/15%
KOSR/5% Fetal Bovine Serum (Heat inactivated, FBS/1 mM
L-glutamine/0.1 mM b-ME/1% NEAA, and by plating AdiPS
or ES cells on ultra low adhesion cell culture plates (CoStar,
Corning) for 7–10 days. EBs were ﬁxed in 4% PFA/4%
sucrose, and either serially dehydrated for parafﬁn histology
or sucrose permeabilized and embedded in OCT for frozen
section analysis and immunohistochemistry. Teratomas were
generated by injecting 2 × 10
6 cells into the hind legs of
8-week SCID mice (Jackson Laboratories). After 3 weeks
(mAdiPS cells) or 7–8 weeks (hAdiPS cells), SCID mice
were euthanized, and the teratomas harvested and processed
for immunostaining. Mouse chimeras were generated by injec-
tion of R1 mES cells into BALB/c recipient blastocysts. Chi-
meras were scored by coat color and tested for germline
transmission. All animal studies were conducted under a
HMS IACUC approved protocol.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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